<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801381</url>
  </required_header>
  <id_info>
    <org_study_id>URO-202001</org_study_id>
    <nct_id>NCT04801381</nct_id>
  </id_info>
  <brief_title>WATER III: Aquablation vs. Transurethral Laser Enucleation of Large Prostates (80 - 180mL) in Benign Prostatic Hyperplasia</brief_title>
  <acronym>WATER III</acronym>
  <official_title>WATER III: A Randomized, Controlled Trial of Aquablation vs. Transurethral Laser Enucleation of Large Prostates (80 - 180mL) in Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PROCEPT BioRobotics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative analysis of efficacy and safety of Aquablation (AQUABEAM Robotic System®, PROCEPT&#xD;
      BioRobotics, Redwood City, CA, USA) and transurethral laser enucleation as surgical therapy&#xD;
      for benign prostatic hyperplasia with large prostates (80-180ml).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective randomized controlled two arm multicenter trial to evaluate the efficacy and&#xD;
      safety of Aquablation (AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA)&#xD;
      compared to transurethral laser enucleation - the current reference standard of minimal&#xD;
      invasive therapy for benign prostatic hyperplasia in large prostates (80-180ml).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2020</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint</measure>
    <time_frame>3 months after index procedure</time_frame>
    <description>Primary efficacy endpoint is defined as IPSS (International Prostate Symptom Score) change</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>Through 3 months after index procedure</time_frame>
    <description>Primary safety endpoint is defined as the occurrence of an Adverse Event rated by the investigator as related or unrelated to the study procedure, classified as Clavien Dindo grade 2 or higher or any grade 1 event resulting in persistent disability, such as ejaculatory or erectile dysfunction or incontinence, as evidenced through 3 months after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in IPSS</measure>
    <time_frame>1,6,12,24,36,48 and 60 months after index procedure</time_frame>
    <description>Change in IPSS (International Prostate Symptom Score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IIEF 5/SHIM</measure>
    <time_frame>3,6,12,24,36,48 and 60 months after index procedure</time_frame>
    <description>Change in IIEF5/SHIM (International Index of Erectile Function)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MSHQ-EjD-SF</measure>
    <time_frame>3,6,12,24,36,48 and 60 months after index procedure</time_frame>
    <description>Change in MSHQ-EjD-SF (Male Sexual Health Questionnaire for Ejaculatory Dysfunction Short Form)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dysuria Questionnaire</measure>
    <time_frame>1,3,6,12,24,36,48 and 60 months after index procedure</time_frame>
    <description>Change in Dysuria Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ICIQ-UI-SF</measure>
    <time_frame>1,3,6,12, 24,36,48 and 60 months after index procedure</time_frame>
    <description>Change in ICIQ-UI-SF (International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post void residual urine</measure>
    <time_frame>day 2-5, 3 months, 6 months, 12 months and 36 months after index procedure</time_frame>
    <description>Reduction of Post void residual urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qmax, Uroflowmetry</measure>
    <time_frame>day 2-5, 3 months, 6 months, 12 months and 36 months after index procedure</time_frame>
    <description>Changes of maximum flow rate (Qmax) measured by Uroflowmetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate volume reduction</measure>
    <time_frame>comparison of Visit 5 (3 months) and visit 1 (baseline)</time_frame>
    <description>Prostate volume reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of re-interventions</measure>
    <time_frame>Through 60 months after index procedure</time_frame>
    <description>Number of re-interventions defined as need for additional tissue resection following the index procedure due to BPH.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>Aquablation therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aquablation therapy: Computer-assisted transurethral ablation of prostate tissue using a high-pressure water jet. Subsequent removal of residual ablated tissue at the bladder neck and haemostasis by transurethral electroresection (TUR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transurethral laser enucleation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transurethral laser enucleation of the prostate using thulium laser (ThuLEP) or holmium laser (HoLEP).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aquablation therapy</intervention_name>
    <description>Aquablation is carried out with the AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA</description>
    <arm_group_label>Aquablation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transurethral laser enucleation</intervention_name>
    <description>Transurethral laser enucleation is performed according to the standard established at the respective test center. Included laser techniques: Holmium laser (HoLEP) and Thulium laser (ThuLEP).</description>
    <arm_group_label>Transurethral laser enucleation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 45 - 80 years&#xD;
&#xD;
          2. International Prostate Symptom Score (IPSS) ≥ 8&#xD;
&#xD;
          3. Prostate size (measurement by transrectal ultrasound): 80 - 180 mL&#xD;
&#xD;
          4. Subject has diagnosis of LUTS (Lower urinary tract symptoms) due to BPH (Benign&#xD;
             Prostatic Hyperplasia)&#xD;
&#xD;
          5. Patient is mentally capable and willing to sign a study-specific consent form&#xD;
&#xD;
          6. Subjects with the ability to follow study instructions and likely to attend and&#xD;
             complete all required visits&#xD;
&#xD;
          7. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Body mass index ≥ 42&#xD;
&#xD;
          2. Suspected or history of prostate cancer&#xD;
&#xD;
          3. Suspected or history of bladder cancer&#xD;
&#xD;
          4. Bladder stone&#xD;
&#xD;
          5. Indwelling catheter for more than 3 months before baseline&#xD;
&#xD;
          6. Active urinary tract infection&#xD;
&#xD;
          7. History of urethral stricture or bladder neck stenosis&#xD;
&#xD;
          8. Damage of the external urethral sphincter&#xD;
&#xD;
          9. Previous prostate surgery or history of lower urinary tract surgery (e.g. urinary&#xD;
             diversion, artificial sphincter or penile prosthesis)&#xD;
&#xD;
         10. Use of anticoagulants (if medication cannot be stopped before and after procedure) or&#xD;
             known coagulopathy (except ASS 100mg/d).&#xD;
&#xD;
         11. Contraindications for general and spinal anaesthesia&#xD;
&#xD;
         12. The investigator considers a pre-existing condition or the subject's life&#xD;
             circumstances to be problematic for the conduct of the study and the completion of the&#xD;
             follow-up investigations&#xD;
&#xD;
         13. Subject is unwilling to accept a blood transfusion if required&#xD;
&#xD;
         14. Subject is not able to give consent&#xD;
&#xD;
         15. Subject without legal capacity who is unable to understand the nature, scope,&#xD;
             significance and consequences of this clinical trial&#xD;
&#xD;
         16. Simultaneously participation in another clinical trial in the field of urology&#xD;
&#xD;
         17. Known or persistent abuse of medication, drugs or alcohol&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Ritter, Univ.-Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, University of Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Stein, Dr. med.</last_name>
    <phone>0049228/28714184</phone>
    <email>johannes.stein@ukbonn.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Urology, Augusta-Kranken-Anstalt, Bochum Mitte</name>
      <address>
        <city>Bochum</city>
        <state>NRW</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burkhard Ubrig, Prof. Dr. med.</last_name>
    </contact>
    <contact_backup>
      <last_name>Simon Gloger, Dr. med.</last_name>
      <phone>0049234 5172651</phone>
      <email>s.gloger@augusta-bochum.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Urology, University of Bonn</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Stein, Dr. med.</last_name>
      <phone>0049228/28714184</phone>
      <email>johannes.stein@ukbonn.de</email>
    </contact>
    <investigator>
      <last_name>Manuel Ritter, Univ.-Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Urologie, Asklepios Westklinikum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22559</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Bach, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>June 13, 2021</last_update_submitted>
  <last_update_submitted_qc>June 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bonn</investigator_affiliation>
    <investigator_full_name>Manuel Ritter</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr. med. Manuel Ritter</investigator_title>
  </responsible_party>
  <keyword>Aquablation therapy</keyword>
  <keyword>Laserenucleation</keyword>
  <keyword>HoLEP</keyword>
  <keyword>ThuLEP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

